- Acasti Pharma Inc KOL Event TranscriptOct 11, 2023
- Acasti Pharma Inc Annual Shareholders Meeting TranscriptOct 10, 2023
- Acasti Pharma Inc at Lytham Partners Spring Investor Conference (Virtual) TranscriptMay 18, 2023
- Acasti Pharma Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Q3 2023 Acasti Pharma Inc Earnings Call TranscriptFeb 14, 2023C$0.83 (-1.19%)Earnings
- Acasti Pharma Inc GTX-101 and GTX-102 Call TranscriptJan 10, 2023
- Q2 2023 Acasti Pharma Inc Earnings Call TranscriptNov 14, 2022C$0.63 (-3.08%)Earnings
- Q1 2023 Acasti Pharma Inc Earnings Call TranscriptAug 11, 2022C$1.15 (+3.60%)Earnings
- Q4 2022 Acasti Pharma Inc Earnings Call TranscriptJun 21, 2022C$1.22 (+0.83%)Earnings
- Acasti Pharma Inc Announces Positive Results for Pharmacokinetic Bridging Study Call TranscriptMay 18, 2022
- Acasti Pharma Inc at B Riley Neuro & Ophthalmology Conference (Virtual) TranscriptApr 28, 2022
- Q3 2022 Acasti Pharma Inc Earnings Call TranscriptFeb 14, 2022C$1.58 (+4.64%)Earnings
- Q2 2022 Acasti Pharma Inc Earnings Call TranscriptNov 10, 2021C$2.06 (-1.90%)Earnings
- Acasti Pharma Inc Planned Acquisition of Grace Therapeutics Inc Call TranscriptAug 04, 2021
- Acasti Pharma Inc Annual Shareholders Meeting TranscriptSep 30, 2020
- Q4 2020 Acasti Pharma Inc Earnings Call TranscriptJun 29, 2020C$5.28 (-13.16%)Earnings
- Q3 2020 Acasti Pharma Inc Earnings Call TranscriptFeb 14, 2020C$6.08Earnings
- Q2 2020 Acasti Pharma Inc Earnings Call TranscriptNov 13, 2019C$21.76 (-4.23%)Earnings
- Q1 2020 Acasti Pharma Inc Earnings Call TranscriptAug 14, 2019C$21.76 (+7.09%)Earnings
- Q4 2019 Acasti Pharma Inc Earnings Call TranscriptJun 26, 2019C$12.24 (+7.75%)Earnings
Acasti Pharma Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
' -
Good afternoon. My name is Jan D'Alvise, and I'm the President and CEO of Acasti Pharma. It's really a pleasure to be a part of the Oppenheimer Annual Healthcare Conference, and I look forward to telling you more about Acasti and providing you with an update on our three drug candidates that we're advancing in the clinic.
But before I get started, I need to mention that I'll be making some forward-looking statements today that are subject to certain risk factors. And as always, if you'd like more information on these risk factors, I would direct you to our website, where you can easily find all of our public disclosures.
With that, let me jump in, and I'll tell you more about Acasti. We are a late-stage specialty pharma company. And we have core technologies around drug formulation and drug delivery that we're applying to marketed compounds.
What we're doing is we're taking these drugs that have been on the market, sometimes for decades, and reformulating them and repurposing them into diseases
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)